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Novelty and Impact:  
Colitis-associated cancer can be reproduced in mice by repeated oral ingestion of dextran 
sulfate sodium solution after intraperitoneal injection of azoxymethane. We provided the 
first definitive evidence to indicate that the CCL3-CCR5 axis-mediated fibroblast   
accumulation is required, in addition to leukocyte infiltration, to induce full-blown 
carcinogenesis in this model. Moreover, this process was blocked by an antagonist of 
CCR5, suggesting its therapeutic potential for cancers accompanied with fibroblast 
accumulation. 






Patients with inflammatory bowel diseases often develop colon carcinoma. Combined 
treatment of azoxymethane (AOM) and dextran sulfate sodium (DSS) recapitulates 
colitis-associated cancer in mice. AOM/DSS-induced tumor formation was reduced in 
CCL3- or its specific receptor, CCR5-deficient mice despite the presence of a massive 
infiltration of inflammatory cells. However, AOM/DSS-induced type I collagen-positive 
fibroblast accumulation in the colon was reduced in CCL3- or CCR5-deficient mice. This 
was associated with depressed expression of heparin-binding epidermal growth factor-like 
growth factor (HB-EGF), which is expressed mainly by fibroblasts. Moreover in vitro, 
CCL3 induced fibroblasts to proliferate and to enhance HB-EGF expression. Furthermore, 
CCR5 blockade reduced tumor formation together with reduced fibroblast accumulation 
and HB-EGF expression, even when administered after the development of multiple colon 
tumors. Thus, CCL3-CCR5-mediated fibroblast accumulation may be required, in addition 
to leukocyte infiltration, to induce full-blown colitis-associated carcinogenesis. This 
process can be blocked by a CCR5 antagonist, which may have therapeutic potential.   





Dvorak proposed that tumor is a wound that does not heal, based on the morphological 
changes shared between wound healing and tumor; consisting of leukocyte infiltration, 
neovascularization, and fibroblast accumulation (1). His hypothesis is corroborated by 
several lines of clinical and experimental evidence supporting the contribution of 
cancer-associated inflammation to tumor development and progression (2). One typical 
example is colitis-associated cancer (CAC), which ensues after chronic intestinal 
inflammation arising from inflammatory bowel disease (IBD) such as ulcerative colitis 
(UC) (3). Pathological features of UC are prolonged and uncontrolled inflammatory 
responses with prominent leukocyte infiltration in the colonic mucosa. These conditions 
frequently cause DNA damage with microsatellite instability in mucosal cells, and 
eventually can progress to cancer (4). Likewise, chronic inflammation can cause cancer in 
other organs, such as asbestosis-related mesothelioma and is estimated to account for 
nearly 20 % of cancer cases (2). Thus, the elucidation of chronic inflammation-associated 
carcinogenesis is important to develop novel therapeutic modalities for various types of 
cancer. 
Oral administration of dextran sulfate sodium (DSS) to rodents can recapitulate 
the pathological changes of human UC (5). Moreover, repeated oral DSS ingestion can 
cause colon carcinoma (6) and this carcinogenesis process is promoted by prior 
administration of azoxymethane (AOM) (7), which causes O6-methyl-guanine formation 
and induces mutations of the  catenin gene (8). Thus, combined treatment with AOM and 
DSS can reproduce CAC in rodents at morphological and molecular levels. We previously 
demonstrated that AOM/DSS-induced CAC is accompanied with massive leukocyte 
infiltration together with enhanced expression of several chemokines including CXCL1 
and CCL2 (9). Moreover, CCL2 blockade decreased intracolonic macrophage infiltration, 
attenuated neovascularization, and eventually reduced the numbers and size of colon 
tumors, even when given after multiple colon tumors have developed (10). These 
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observations revealed an indispensable role of a chemokine, CCL2, in the initiation and 
progression of CAC. 
Evidence is accumulating to indicate that cancer-associated fibroblasts (CAFs), 
the fibroblasts in tumor tissues, also have a crucial role in tumor development and 
progression (11).  In the AOM/DSS-induced CAC model, the contribution of 
CAF-derived growth factors has been documented (12, 13). However, the mechanism 
regulating CAF trafficking in AOM/DSS-induced CAC remains unclear. We observed that 
AOM/DSS treatment enhanced the intracolonic expression of another chemokine, CCL3, 
which can exhibit biological effects on leukocytes and non-leukocyte cells, particularly 
fibroblasts (14, 15). Hence, we investigated the roles of the CCL3 axis in this CAC model 
and demonstrated that CCL3 and its specific receptor, CCR5, have crucial roles in CAF 
accumulation in AOM/DSS-induced CAC. Moreover, we provided the first definitive 
evidence to indicate that leukocyte infiltration is not sufficient, but that the 
CCL3-CCR5-mediated fibroblast accumulation is additionally required to induce 
full-blown CAC. 
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Material and Methods 
 
Mice 
Specific pathogen-free seven week-old female Balb/c mice were purchased from Charles 
River Laboratories (Yokohama, Japan) and were designated as wild-type (WT) mice. 
CCR5-deficient mice were generated as previously described (16). CCR1-deficient mice 
(17) were provided by Dr. P. Murphy (NIAID, NIH, Bethesda, MD). CCL3-deficient mice 
(18) were obtained from the Jackson Laboratory (Bar Harbor, ME). These gene-deficient 
mice were backcrossed to Balb/c for more than eight generations. All mice were kept under 
specific pathogen-free conditions with free access to food and water. 
 
AOM/DSS-induced colon carcinogenesis model 
Pathogen-free 8- to 12-week old female WT, CCL3-, CCR1-, or CCR5-deficient mice were 
injected intraperitoneally with 12 mg/kg body weight of AOM dissolved in physiological 
saline. Five days thereafter, 3.0 % or 4.5 % DSS was given in the drinking water over 5 
days, followed by 16 days of regular water and this cycle was repeated a total of 3 times. 
Body weights were measured every day, and the animals were sacrificed at the indicated 
time intervals for macroscopical inspection, histological analysis, and total RNA extraction  
followed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The 
detailed procedures of in vivo gene transduction are described in Supplementary Methods. 
 
Tumor inoculation 
A murine adenocarcinoma cell line, colon 26 (19), was maintained in RPMI with 10% 
heat-inactivated fetal bovine serum. Sub-confluent cells were collected and resuspended in 
HBSS. The cell viability was confirmed to be always > 95% by a trypan blue exclusion test. 
One hundred fifty μl of cell suspensions (50 × 104 cells/head) were injected subcutaneously 
(s.c.) into the back of WT, CCR1- or CCR5-deficient mice. Tumor sizes were measured 
every 3 to 4 days using calipers. Tumor volumes were calculated according to an equation 
of a × b2/2, where a and b indicate long and short diameters of the tumor, respectively (20). 
CCL3-CCR5 axis in colon carcinogenesis  Sasaki et al. 6 
 
  
Fourteen days after tumor cell injection, tumors were removed for immunohistochemical 
analysis or enzymatically digested using collagenase type I for single cell preparation to 
conduct a flow cytometry. In another series of experiments, 40 l of cell suspensions (10 x 
104 cells/head) were administered to cecum of WT or CCR5-deficient mice. Fourteen days 
after tumor cell injection, cecum was removed for determination of tumor volume and 
immunohistochemical analysis. 
 
Isolation of murine fibroblasts from colon tissues 
Detailed information on isolation of murine fibroblasts is provided in Supplementary 
Methods. 
 
Reagents and plasmids 
Detailed information on the used reagents and plasmids is provided in Supplementary 
Methods. 
 
Immunohistochemical analysis and qRT-PCR 




Statistical significance was evaluated using one-way ANOVA, followed by Tukey-Kramer 
post-hoc test or Dunnet’s test. p values less than 0.05 were considered statistically 
significant. 
  





Reduction in AOM/DSS-induced colonic tumorigenesis in CCL3 or CCR5-deficient 
mice. WT mice given 3.0 % DSS to ingest exhibited a marked body weight loss 
synchronizing with DSS ingestion (Supplementary Fig. 1). As we previously observed (9, 
10), tumors emerged in the colon at 35 days after the initiation of DSS intake, increasing in 
numbers and size, thereafter, and extending from the middle to distal colon of WT mice at 
56 days (Fig. 1A). Given our previous observations indicating the crucial involvement of a 
macrophage-tropic chemokine, CCL2-mediated macrophage infiltration in this 
carcinogenesis (10), we investigated the expression of another macrophage-tropic 
chemokines, CCL3, CCL4, and CCL5, and their receptors, CCR1 and CCR5. CCL3, CCR1, 
and CCR5 mRNA expression levels were augmented in WT mice during the whole course 
of this carcinogens process, while CCL4 and CCL5 mRNA expression was transiently 
enhanced but returned to basal level after 35 days when tumor appeared (Fig. 1B). In order 
to determine the roles of the CCL3 axis, if any, we gave 3.0 % DSS after AOM injection to 
CCL3-, CCR1-, or CCR5-deficient mice. Three % DSS failed to induce a marked body 
weight loss (Supplementary Fig. 1) and a large number of tumor formation in CCL3-, 
CCR1-, or CCR5-deficient mice (Fig. 1A, 1C, and 1D). When the DSS concentration was 
increased to 4.5 %, all WT mice succumbed to death until 10 days after the first DSS intake, 
while CCL3-, CCR1- or CCR5-deficient mice exhibited a marked body weight loss 
synchronizing with DSS ingestion but survived until 56 days (Supplementary Fig. 2). 
Eventually, CCR1-deficient mice developed a large number of colon tumors, whereas the 
numbers and size of colon tumors were markedly lower in CCL3- or CCR5-deficient mice 
(Fig. 1A, 1C, and 1D). However, severe body weight loss would indicate that CCL3-, 
CCR1- or CCR5-deficient mice developed similar inflammatory reactions when they were 
given 4.5 % DSS. This assumption was corroborated by the observations that 
Ly6G-positive granulocytes and F4/80-positive macrophages infiltrated to a similar extent 
in these three strains when they were given 4.5 % DSS (Fig. 2A). Thus, leukocyte 
infiltration may be necessary, but not sufficient, to induce full-blown AOM/DSS-induced 
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CAC in CCL3- or CCR5-deficient mice. Moreover, a double-color immunofluorescence 
revealed that CCL3 expression was detected on Ly6C-positive cells and -smooth muscle 
actin (SMA)-positive cells (Fig. 2B). 
 
Reduced tumor formation correlates with attenuated fibroblast accumulation in the 
absence of the CCL3 axis. Cancer-associated inflammatory responses consist of 
fibroblast accumulation as well as leukocyte infiltration (1). In order to prove the roles of 
fibroblast accumulation in this carcinogenesis model, we evaluated fibrotic changes in this 
colon carcinogenesis model. In mice given 4.5 % DSS, collagen deposition was increased 
in CCR1- but not CCL3- or CCR5-deficient mice as revealed by Masson’s staining (Fig. 
3A). Moreover, larger numbers of intratumoral type I collagen-positive cell numbers were 
observed in CCR1-deficient mice than CCL3- or CCR5-deficient mice (Fig. 3A and 3B). 
The intake of 3.0 % DSS after AOM injection did significantly increase type I 
collagen-positive cells in WT mice on and after 49 days but not at 35 days (Fig. 3C). Thus, 
fibroblast accumulated after tumors started to appear in colon. On the contrary, type I 
collagen-positive cell numbers were not increased until 56 days in the mice deficient in 
CCL3 or CCR5 gene (Fig. 3C), as similarly observed when these mice were given 4.5 % 
DSS (Fig. 3B). Moreover, a double-color immunofluorescence analysis detected CCR5 
expression on type I collagen-positive cells (Fig. 3D), consistent with our previous 
observation on lung fibroblasts at lung metastasis sites (15). We previously proved that 
CCL3 can induce the migration of fibroblasts in a CCR5-dependent manner (15). We 
further demonstrated that CCL3 enhanced the in vitro proliferation of fibroblasts derived 
from colon tissues as well as TNF- (Fig. 3E). These observations would indicate that 
CCL3-CCR5-mediated fibroblast accumulation is required, in addition to leukocyte 
infiltration, to induce full-blown colon carcinogenesis, particularly in the later phase. 
 
Reduction in AOM/DSS-induced HB-EGF expression in CCL3- or CCR5-deficient 
mice. Several lines of evidence indicate that fibroblasts can produce various growth 
factors including hepatocyte growth factor (HGF), epiregulin (EREG), basic fibroblast 
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growth factor (bFGF), and HB-EGF to promote tumor progression (21-23). Because 
fibroblast accumulation was not evident at 35 days, we examined the expression of these 
factors on and after 35 days. However, we failed to observe differences in HGF, bFGF, and 
EREG mRNA expression among WT, CCL3-, or CCR5-deficient mice on and after 35 days 
after DSS injection (Supplementary Fig. 3). On the contrary, HB-EGF mRNA and protein 
expression was depressed in CCL3- or CCR5-deficient mice, compared with WT mice on 
and after 49 days (Fig. 4A and 4B), when fibroblast accumulation was evident in WT mice. 
We further examined mRNA expression of other fibroblast-related molecules such as 
tenascin C (24), matrix metalloproteinase (MMP)-2 (25), MMP-9 (25), and CXCL1 and 
CXCL2, mouse functional homologues of IL-8/CXCL8 (26). Among these molecules, only 
CXCL1 and CXCL2 expression was enhanced during AOM/DSS-induced carcinogenesis 
and the increases were attenuated in CCL3- or CCR5-deficient mice (Supplementary Fig. 3). 
A double-color immunofluorescence analysis demonstrated that type I collagen-positive 
cells expressed HB-EGF (Fig. 4C). Moreover, HB-EGF mRNA was detected selectively in 
the tumor tissue-derived cell fraction expressing mRNA of type I collagen- and 
platelet-derived growth factor receptor  chain (PDGFR), selective markers of fibroblasts 
(Figure 4D). Furthermore, CCL3 enhanced HB-EGF expression in colon-derived 
fibroblasts as well as TNF- (Fig. 4E), suggesting that CCL3 can sustain HB-EGF 
expression in fibroblasts accumulated in colon tumor. Finally, we in vivo transduced 
HB-EGF gene into CCL3-deficient mice at 42 days after the initiation of DSS intake. 
HB-EGF-expression but not control vector transduction increased the tumor numbers 
(Figure 4F) with few effects on type I collagen-positive cell numbers (Supplementary Fig. 
4). These observations suggest that HB-EGF could directly promote tumor formation. 
 
Reduced fibroblast accumulation and tumor formation by CCR5 blockade. In 
order to address the effects of the CCR5 blockade on tumor progression, we injected  
colon 26 cells s.c. into WT, CCR1-, or CCR5-deficient mice. Tumor formation was 
significantly depressed in CCR5-deficient mice, compared with WT or CCR1-deficient 
mice (Fig. 5A), but with little suppression on the infiltration of F4/80-positive macrophages 
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and Ly6G-positive granulocytes (Fig. 5B and 5C). On the contrary, type I collagen-positive 
cell and Ly6C-positive cell numbers were reduced in CCR5-deficient mice, compared with 
WT or CCR1-deficient mice (Fig. 5D and E). Similarly, tumor formation was significantly 
depressed in CCR5-deficient mice together with reduced intratumoral type I 
collagen-positive cell numbers, compared with WT when colon 26 cells were injected into 
the cecum (Figure 5F and 5G). Finally, we systemically expressed truncated 
(t)RANTES/CCL5 by using hydrodynamic tail vein injection technique (27, 28) at 56 days 
after AOM/DSS treatment, when multiple tumors have developed in the colon. Under these 
conditions, systemic tRANTES/CCL5 expression resulted in sustained expression of this 
CCR5 antagonist in serum until 70 days after the treatment (Supplementary Fig. 5). Type I 
collagen-positive cell accumulation, HB-EGF expression, and subsequent tumor formation 
were significantly reduced, even when the vector was administered after multiple colon 
tumors have developed (Fig. 6A to 6D). However, tRANTES/CCL5 had few effects on the 
numbers of Ly6G-positive granulocytes and F4/80-positive macrophages in tumors (Fig. 
6E and 6F). These observations further support our conclusion that the CCL3-CCR5 axis 
could regulate fibroblast accumulation and HB-EGF expression in fibroblasts and that both 
processes were crucial for tumor progression. 




CAC can ensue from persistent colonic inflammation consisting of submucosal 
edema and a massive leukocyte infiltration into the mucosa. Accumulating evidence 
implicates the crucial roles of infiltration of leukocytes including neutrophils and 
macrophages in cancer development in AOM/DSS-induced CAC model (9, 10). Similarly, 
as observed in TNF-Rp55- or CCR2-deficient mice (9, 10), we observed that neutrophil 
infiltration and subsequent tumor formation was remarkably reduced in CCL3-, CCR1-, or 
CCR5-deficient mice, which were given 3.0 % DSS solution, compared with WT mice. Of 
interest is that 4.5 % DSS intake induced a marked infiltration of granulocytes and 
macrophages in these three strains, to a similar extent as WT mice given 3.0 % DSS. 
However, only CCR1-deficient mice developed tumors equally as well as WT mice given 
3.0 % DSS. These observations would indicate that leukocyte infiltration may be necessary, 
but not be sufficient to induce full-blown CAC. 
Chemokines were originally identified as regulators of leukocyte trafficking, but 
subsequent studies unraveled their profound effects on other types of cells including 
endothelial cells and fibroblasts, the cells that contribute, in collaboration with leukocytes, 
to inflammatory responses including cancer-associated inflammation (29). Moreover, we 
previously observed that fibroblasts express CCR5 and exhibit chemotaxis in response to 
CCL3 in a CCR5-dependent manner (15). Hence, we investigated the fibrotic changes in 
colon after AOM/DSS treatment. We demonstrated that fibroblast accumulation was 
evident after tumors formed in colon and that it was remarkably reduced in CCL3- or 
CCR5-deficient mice, compared with WT or CCR1-deficient mice. Likewise, 
CCR5-deficient mice exhibited reduced tumor growth with attenuated fibroblast 
accumulation, compared with WT or CCR1-deficient mice when a mouse colon 
adenocarcinoma cell line was injected s.c. or into cecum. Thus, the CCL3-CCR5-mediated 
fibroblast accumulation can be additionally required for colon carcinogenesis, particular in 
its progression phase. 
CAFs, fibroblasts present in tumor tissues, can be activated by paracrine signals to 
produce various growth factors (11). TNF- is expressed often abundantly in tumor tissues 
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and can activate CAFs to express various cytokines and chemokines (30). We previously 
detected TNF- expression in colon tissues in this model  (9). Indeed, TNF- in vitro 
augmented cell proliferation and HB-EGF expression in colonic fibroblasts equally as well 
as CCL3. Thus, CCL3, like TNF can have profound impacts on fibroblast functions, such 
as migration, proliferation, and growth factor expression, thereby promoting mainly tumor 
progression. 
CAFs consist of heterogeneous populations with diverse origins; locally resident 
fibroblasts, cells undergoing epithelial-mesenchymal transition, and bone marrow-derived 
fibrocytes (11, 31). We previously demonstrated that both fibroblasts and type I 
collagen-positive CD45-positive fibrocytes exhibited a chemotactic response to CCL3 in a 
CCR5-dependent manner (14, 15). Although we detected CCR5 expression by fibrocytes 
as well as fibroblasts in colon tissues, fibrocytes were remarkably less numerous than 
fibroblasts in colon tissues after AOM/DSS treatment (our unpublished data). Considering 
that CCL3 can promote fibroblast proliferation, it may be more plausible that the 
CCL3-CCR5 axis acts mainly on resident fibroblasts in colon tissues.  
CAFs produce various growth factors to promote cancer cell growth. 
Accumulating evidence indicates that fibroblasts are a major source of HGF (32). We also 
reported HGF production by lung fibroblasts in the mouse lung metastasis model (15), but 
we could not detect enhanced HGF expression in colon after AOM/DSS treatment, 
consistent with the previous report (12). CAF-derived epiregulin is proposed to be 
crucially involved in AOM/DSS-induced neoplasms by activating mitogen-activated 
protein kinase (MAPK) pathway (13). However, we failed to observe a sustained elevation 
of epiregulin and the effects of CCL3 or CCR5 deficiency on its expression in colon. On the 
contrary, HB-EGF expression was markedly attenuated in CCL3- or CCR5-deficient mice, 
implying that the CCL3-CCR5 axis can regulate HB-EGF expression by fibroblasts in 
colon. This assumption is further corroborated by the ability of CCL3 to induce HB-EGF 
expression in vitro in fibroblasts. 
HB-EGF belongs to epidermal growth factor (EGF) family of growth factors (33). 
Like other EGF family members, HB-EGF is initially synthesized as a transmembrane 
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precursor protein and is cleaved at the cell surface by a protease to yield the soluble form 
by ectodomain shedding (34). The receptors for EGF family members possess tyrosine 
kinase activity and comprise four members; EGF receptor (EGFR)/ErbB1, ErbB2, ErbB3, 
and ErbB4 (35). HB-EGF binds predominantly EGFR and ErbB4 to exert its biological 
effects. EGFR is expressed ubiquitously by various types of epithelial cells although the 
cellular distribution of ErbB4 still remains to be investigated. Immunohistochemical 
analyses detected HB-EGF protein in various types of cancer cells including pancreatic 
(36), hepatocellular (37), colonic (38), gastric (39), and ovarian cancer cells (40). However, 
in uterine cervical cancer tissues, HG-EGF was expressed primarily in stromal fibroblasts, 
rather than cancer cells (21), consistent with our observation that HB-EGF was 
predominantly expressed in type I collagen-positive cells. Thus, fibroblast-derived 
HB-EGF can act on cancer cells to activate MAPK, P13-Akt, Src and Stat pathways, which 
exist downstream of its receptors (33, 34), leading to excessive cell growth and invasion, in 
a paracrine manner. This notion was corroborated by our present observation that in vivo 
HB-EGF gene transduction markedly enhanced tumor formation in CCL3-deficient mice 
with few effects on fibroblast accumulation at the time, when tumor started to emerge. 
Several lines of evidence indicate that HB-EGF can activate NF-B (41, 42), the 
transcription factor which is activated most frequently in both inflammatory responses and 
carcinogenesis (43). Greten and colleagues revealed that NF-B is activated in both 
intestinal epithelial cells and infiltrating macrophages in AOM/DSS-induced colon 
carcinogenesis (44). NF-B activation in intestinal epithelium mediates anti-apoptotic 
effects, which can prevent the elimination of premalignant cells  (44), in which the 
-catenin pathway is activated due to mutations in its gene. Moreover, they demonstrated 
that chronic epithelial NF-B activation can enhance inducible NO synthase-mediated 
DNA damage to accelerate APC loss (45). Thus, in addition to its direct mitogenic effects 
on epithelial cells, HB-EGF can promote colon carcinogenesis by activating NF-B. 
We utilized the in vivo gene transduction of tRANTES/CCL5, which can 
antagonize the interaction between CCR5 and CCR5-binding chemokines, CCL3, CCL4, 
and CCL5 (46), in order to block CCR5-mediated signals in this model. It is interesting that 
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tRANTES/CCL5 gene transduction reduced the tumor numbers even when it was 
administered after multiple tumors already developed. These observations would indicate 
that colon cancer, particularly CAC, can be treated with a CCR5 antagonist with a small 
molecular weight, which has been used for the treatment of AIDS patients and is well 
tolerated (47, 48). Moreover, tRANTES/CCL5 simultaneously attenuated fibroblast 
accumulation and HB-EGF expression, with few effects on the infiltration of granulocytes 
and macrophages, the cells which are presumed to have crucial roles in this colon 
carcinogenesis (9, 10). Thus, the selective blockade of fibroblast trafficking and/or 
functions may be effective in counteracting the progression of cancer characterized by the 
presence of abundant CAFs. 
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Legends to Figures 
 
Figure 1 The involvement of the CCL3-CCR5 axis in AOM/DSS-induced colon 
carcinogenesis. A. Macroscopic and microscopic appearances of colon of WT, CCL3-, 
CCR1-, and CCR5-deficient mice after AOM/DSS treatment. Colons were removed from 
WT mice at 56 days after the mice were given either 3.0 % or 4.5 % DSS in combination 
with AOM pretreatment. Macroscopic appearances of colon tissues are shown in the upper 
panels, while HE-stained colon tissues are shown in the lower panels. Insets indicate 
enlarged area of tumor sites. Scale bars represent 100 μm. Representative results from 10 
independent animals are shown here. B. CCL3, CCL4, CCL5, CCR1 and CCR5 gene 
expression in the colons of WT mice. The levels of mRNA were quantified by qRT-PCR 
from the colon obtained at the indicated time intervals and normalized to the level of HPRT 
mRNA. Data represent the mean + SEM (n=5 animals). *, p<0.05; **, p<0.01 vs. untreated. 
C. Tumor numbers after AOM/DSS treatment. Colons were removed at 56 days after the 
mice were given either 3.0 % or 4.5 % DSS in combination with AOM pretreatment, to 
determine the numbers of macroscopic tumors. Data represent the mean + SEM (n=5 
animals). **, p<0.01; n.s., not significant. D. Tumor size after AOM/DSS treatment. 
Colons were removed at 56 days after the mice were given 3.0 % or 4.5 % DSS in 
combination with AOM pretreatment, to determine the size of macroscopic tumors. Each 
symbol represents the size of tumors. The bars represent the average of each group. *, 
p<0.05; n.s., not significant. 
 
Figure 2 Inflammatory cell infiltration and CCL3-expressing cells after AOM/DSS 
treatment. A. Colons were removed at 49 days after the mice were given either 3.0 % or 
4.5 % DSS combined with AOM pretreatment. The obtained tissues were fixed and 
immunostained with either anti-Ly6G or anti-F4/80 antibodies to determine the numbers of 
Ly6G-positive granulocytes (left panel) or F4/80-positive macrophages (right panel), 
respectively. All values represent the mean + SEM (n=10 animals). *, p<0.05, n.s., not 
significant.  B. Immunofluorescence detection of CCL3-expressing cells. Colons were 
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obtained from WT mice at 49 days after the initiation of DSS treatment. Double-color 
immunofluorescence analysis was conducted with the combination of anti-CCL3 and 
anti-F4/80 (top row), that of anti-CCL3 and anti-Ly6C (middle row), or that of anti-CCL3 
and anti-SMA (bottom row). Representative results from 5 independent experiments are 
shown here. Scale bars represent 100 μm. 
 
Figure 3 The effects of the CCL3-CCR5 axis on fibroblasts. A. Colons were removed at 56 
days after the mice were given 4.5 % DSS combined with AOM pretreatment. The obtained 
tissues were fixed, and immunostained with anti-type I collagen antibodies (upper panels) 
or were stained with Masson’s trichrome solution (lower panels). Representative results 
from 5 mice are shown here. Scale bars represent 100 μm. B. Type I collagen-positive areas 
were determined inside tumor tissues of colon obtained at 56 days after the mice were 
given 4.5 % DSS combined with AOM pretreatment. All values represent the mean + SEM 
(n=5 animals). *, p<0.05, **, p<0.01. C. Type I collagen-positive areas were determined 
inside colon tumor tissues or the corresponding colon tissues obtained at the indicated time 
intervals after the mice were given 3.0 % DSS combined with AOM pretreatment. All 
values represent the mean + SEM (n=5 animals). *, p<0.05, **, p<0.01, n.s., not significant. 
D. Immunofluorescence detection of CCR5-expressing cells. Colons were obtained from 
WT mice at 56 days after the initiation of DSS treatment. Double-color 
immunofluorescence analysis was conducted with the combination of anti -CCR5 and 
anti-F4/80 (top row) or that of anti-CCR5 and anti-type I collagen antibodies (bottom row). 
Representative results from 5 independent experiments are shown here. Scale bars 
represent 100 μm. E. CCL3-induced fibroblast proliferation. Fibroblasts were incubated in 
the presence of CCL3 (100 ng/ml) or TNF- (1 ng/ml) for 2 days. The results are shown 
with the ratio compared to medium-treated sample. All values represent the mean + SD 
(n=5). *, p<0.05. 
 
Figure 4. HB-EGF expression and its role in carcinogenesis. A. The levels of HB-EGF 
mRNA were quantified by qRT-PCR on total RNAs extracted from the colon of WT, CCL3-, 
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or CCR5-deficient mice and normalized to the level of HPRT mRNA. All values represent 
the mean + SD (n=5 animals). *, p<0.05, WT vs. CCL3- or CCR5-deficient mice. B. 
HB-EGF protein expression in the colons of mice. Colon tissues were obtained from WT, 
CCL3-deficient, and CCR5-deficient mice and the levels of HB-EGF protein in the colon 
extracts were quantified by using ELISA. All values represent the mean + SD (n=3 
animals). *, p<0.05, WT vs. CCL3- or CCR5-deficient mice. C. Double-color 
immunofluorescence analysis was conducted with the combination of anti-type I collagen 
and anti-HB-EGF antibodies. Signals were digitally merged. Representative results from 5 
independent experiments are shown here. Scale bars represent 100 μm. D. Total RNAs 
were extracted from the colon tumor tissues obtained from CD31- and CD45-positive 
fibroblast-enriched fraction and unseparated cell fraction to determine HB-EGF, type I 
collagen, PDGFR mRNA expression by qRT-PCR and normalized to the level of HPRT 
mRNA. All values represent the mean + SD (n=5). *, p<0.05. E. CCL3-induced HB-EGF 
expression in fibroblasts. Fibroblasts were obtained from colon as described in 
Supplementary Methods and were incubated in the presence of CCL3 (100 ng/ml) or 
TNF- (1 ng/ml) for 2 days. HB-EGF mRNA was quantified by qRT-PCR and normalized 
to the level of GAPDH mRNA. All values represent the mean + SEM (n=5). *, p<0.05.  F. 
HB-EGF pLIVE vector was in vivo transduced to CCL3-deficient mice at 42 days after the 
initiation of DSS intake. At 56 days after the initiation of DSS intake, colons were removed 
to determine the numbers of macroscopic tumors. All values represent the mean + SD (n=5 
animals). *, p<0.05. 
 
Figure 5. Reduced tumor formation in CCR5-deficient mice after injection of colon 26 
cells.  A. to E. A mouse colon adenocarcinoma cell line, colon 26, were injected s.c. into 
WT, CCR1-deficient, or CCR5-deficient mice. A. Tumor volumes were determined at the 
indicated time intervals. All values represent the mean ± SD (n=5 animals). *, p<0.05; **, 
p<0.01.  B. to D. Tumor tissues were obtained at 14 days after the tumor inoculation, to 
determine the numbers of intratumoral F4/80-positive macrophages (B) or Ly6G-positive 
granulocytes (C) and type I collagen-positive areas (D). All values represent the mean + SD 
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(n=5 animals). *, p<0.05, **, p<0.01, n.s., not significant. E. Single cell populations were 
obtained from tumor tissues and were subjected to a flow cytometric analysis to determine 
Ly6C-positive cell numbers. All values represent the mean + SD (n=5 animals). *, p<0.05. 
F. and G. Reduced tumor formation and fibroblast accumulation in CCR5-deficient mice 
after orthotopic injection of colon 26 cells into cecum. F. Cecum was obtained at 14 days 
after the injection to determine the tumor volumes macroscopically. Each symbol 
represents the size of tumors. G. Type I collagen-positive areas inside tumor tissues were 
determined on the cecum obtained at 14 days after the injection. All values represent the 
mean + SD (n>5 animals). *, p<0.05. 
 
Figure 6. Reduced tumor formation by CCR5 blockade. WT mice were treated with 3.0 % 
DSS in combination with AOM pretreatment. At 56 days after the initiation of DSS intake, 
the mice were administered with either tRANTES/CCL5 expression or control vector. A. 
Animals were sacrificed to obtain colon at each time point until 77 days after the initiation 
of DSS intake, to determine tumor numbers macroscopically. All values represent the mean 
+ SD (n=5 animals) *, p<0.05.  B. to F. Twenty-one days after either tRANTES/CCL5 
expression or control vector administration (77 days after the initiation of DSS intake), 
colon was removed to determine type I collagen-positive areas (B), HB-EGF mRNA 
expression normalized to the level of HPRT (C), HB-EGF protein levels (D), 
Ly6G-positive granulocyte numbers (E), F4/80-positive macrophage numbers (F). All 
values represent the mean + SD (n=5 animals). *, p<0.05; n.s., not significant. 
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Reagents and antibodies 
AOM and DSS (MW 36,000–50,000) were purchased from Sigma-Aldrich (St. Louis) and 
MP Biochemicals Inc. (Auroa), respectively. Mouse CCL3 and TNF- were obtained from 
Peprotech Inc. (Rocky Hill). The following antibodies were used as the primary antibodies 
for immunohistochemical or immunofluorescence analyses: goat anti-mouse CCL3 
antibody (R&D Systems); goat anti-mouse CCR5 antibody (Santa Cruz Biotechnology); 
mouse anti-mouse  smooth muscle actin (SMA) antibody (DAKO); rat anti-mouse Ly6C 
antibody (Abcam); rat anti-mouse F4/80 antibody (Serotec); rat anti-mouse Ly6G antibody 
(BD Biosciences); rabbit anti-HB-EGF antibody (Bioss); rabbit anti-type I collagen 




Mouse CCL5 (RANTES) cDNA, which lacks amino-terminal 8 residues, and mouse 
heparin-binding epidermal growth factor-like growth factor (HB-EGF) cDNA were cloned 
by reverse transcriptase (RT)-PCR using mouse lung tissue-derived mRNA as a template. 
The resultant cDNA was inserted into pLIVE-vector (Mirus Corporation) to generate the 
truncated (t)RANTES/CCL5-pLIVE vector that can express tRANTES/CCL5 protein 
linked with a Flag tag in its carboxyl-terminal portion or HB-EGF-pLIVE vector. 
pLIVE-vector without any insert was used as a control plasmid. All the plasmids were 
isolated by using a Plasmid DNA Purification kit (MACHEREY-NAGEL GmbH). 
 
In vivo transduced gene mouse mode 
In some experiments, at 56 days after the initiation of the first DSS intake, WT mice were 
injected with either tRANTES/CCL5-pLIVE or control vector at a dose of 10 g/head by 
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using TransIT-EE Hydrodynamic Delivery Solution (Mirus Corporation) according to the 
manufacturer’s instructions (1, 2). In another series of experiments, at 42 days after the 
initiation of the first DSS intake, CCL3-deficient mice were injected with either 
HB-EGF-pLIVE or control vector at a dose of 10 g/head by using TransIT-EE 
Hydrodynamic Delivery Solution. Plasma tRANTES/CCL5 levels were determined by 
using a commercially available ELISA kit against mouse CCL5 (R&D Systems). All 
animal experiments were approved by the Committee on Animal Experimentation of 
Kanazawa University and performed in compliance with the Kanazawa University’s 
Guidelines for the Care and Use of Laboratory Animals. 
 
Immunohistochemical analyses of mouse colon tissues 
Resected mouse colon tissues were fixed in Tissue-Tek Ufix (Sakura Fine Technical Co.) 
for paraffin embedding or were immediately frozen in Tissue-Tek O.C.T. compound 
(Sakura Fine Technical Co.) to be stored at -80°C. Paraffin-embedded sections were cut at 3 
μm thickness and stained with hematoxylin and eosin solution. In addition, 5 μm-thick 
sections were made and stained with Masson’s trichrome solution (Sigma-Aldrich) for the 
detection of collagen deposition. Frozen sections were fixed in ice-cold methanol for 5 
minutes for an immunohistochemical analysis. For antigen retrieval of paraffin sections, 
the deparafinized slides were either autoclaved in 10 mmol/L citrate buffer (pH 6.0) for 5 
min at 121oC (anti-type I collagen), treated with 0.1% proteinase K solution for 15 min at 
37oC (anti-Ly6C, anti-CCL3, or anti-CCR5), or treated with 0.1% trypsin solution for 15 
min at 37 oC (anti-F4/80 or anti-Ly6G). Endogenous peroxidase activity was blocked using 
0.3% H2O2 for 15 minutes, followed by incubation with Blocking One Histo (Nacalai 
Tesque) for 15 minutes. The sections were incubated with the optimal dilution of the 
antibody overnight in a humidified box at 4°C. The resultant immune complexes were then 
detected by the ABC Elite kit (Vector Laboratories) and peroxidase substrate 
3,3’-diaminobenzidine kit (Vector Laboratories), according to the manufacturer’s 
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instructions. Positive signals or areas were measured on 5 randomly chosen visual fields at 
x 100 magnification by means of Image J. For a double-color immunofluorescence analysis, 
Alexa Fluor 546 donkey anti-goat, Alexa Fluor 594 donkey anti-rabbit or Alexa Fluor 488 
donkey anti-rat antibodies were used as secondary antibodies. Immunofluorescence was 
visualized on an OLYMPUS BX50/DP70. Double-color immunostaining with anti-rabbit 
HB-EGF and anti-rabbit type I collagen staining was conducted by using Zenon Rabbit IgG 
Labeling Kits (Invitrogen), according to the manufacturer’s instructions. 
 
qRT-PCR analysis 
Total RNAs were extracted from the colon tissue using RNeasy Mini Kit (Qiagen). After 
treatment with RNase-free DNase I (Qiagen), 2 g of total RNA was reverse-transcribed 
using SuperScript III First-Strand Synthesis System (Invitrogen) to obtain cDNA. 
qRT-PCR was performed on the obtained cDNA using StepOne real-time PCR system 
(Applied Biosystems) using Fast SYBR Green PCR Master mix (Applied Biosystems) and 
the primers listed in Supplementary Table S1.  Expression levels of the target genes were 
analyzed through the ΔΔCT comparative threshold method. Hypoxanthine phosphoribosyl 
transferase (HPRT) gene or GAPDH was used as an internal control. 
 
Determination of HB-EGF concentration in colon tissues 
At the indicated time intervals, colon tissues were collected and homogenized with a lysis 
buffer (20 mM Tris-HCl, pH 7.6; 150 mM NaCl; 1 % Triton; and 1 mM EDTA) containing 
Complete Protease Inhibitor Cocktail (Roche-Diagnostics). Homogenates were centrifuged 
to obtain protein lysates. After determination of the protein concentration by BCA Protein 
Assay Kit (Pierce), the resultant protein lysates were used to determine their concentrations 
of HB-EGF with the help of enzyme-linked immunosorbent assay (ELISA) kit for HB-EGF 




Isolation of murine fibroblasts for in vitro culture 
The colon was collected from the mice and was opened longitudinally. Then, the tissues 
were washed to remove fecal contents, and were shaken in HBSS containing 5 mM EDTA 
for 20 min at 37°C. After removing epithelial cells and fat tissue, the intestines were further 
cut into small pieces and incubated with Fibroblast Medium Kit (CELLnTEC) at 37°C for 
3 days. Thereafter, unattached cells were removed by washing, and the medium was 
replaced with the same fresh medium. The cells were incubated for additional 4 days until 
becoming confluent. Then, the cells were detached by treatment with 0.25 % trypsin for 2–
3 min at 37 °C and were split at a ratio of 1:2 or 1:3. Cells were maintained in Fibroblast 
Medium and subcultured every 7 to 10 days. By the third passage, the cells formed 
homogeneous monolayers morphologically consistent with fibroblast-like cells and were 
confirmed to consist of >90% type I collagen-positive cells. Colon fibroblasts were used 
for in vitro culture experiments at a confluence between the third and sixth passage.  
 
Preparation of the fibroblast-enriched cell fraction 
Colon tumor tissues were obtained from the mice at 56 days after the initiation of DSS 
intake and were opened longitudinally. Then, the tissues were washed to remove fecal 
content, and were shaken in HBSS containing 5 mM EDTA for 20 min at 37°C. After 
removing epithelial cells and fat tissues, the intestines were further cut into small pieces 
and incubated with RPMI 1640 containing 4% FBS, 1 mg/ml collagenase type I, 1 mg/ml 
dispase, and 40g/ml DNase I for 1 hr at 37 °C in a shaking water bath. After being washed 
with HBSS containing 5mM EDTA, the tissues were resuspended in 5 ml of 40% Percoll 
(GE Healthcare) and were overlaid on 2.5 ml of 80 % Percoll in a 15-ml tube. After 
centrifugation at 2,000 rpm for 20 min at room temperature, the cells in the interface of the 
Percoll gradients were collected and were washed twice with PBS. The resulting single-cell 
suspensions were incubated with the combination of FITC-conjugated rat anti-mouse CD31 
mAb (BD Biosciences) and PerCP-conjugated rat anti-mouse CD45 mAb (eBioscience, 
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Headquarters, USA) for 20 minutes on ice. Isotype-matched control immunoglobulins were 
used to detect nonspecific binding of immunoglobulin. CD31- and CD45-gated cells were 
sorted on a FACS Aria (BD Biosciences) as fibroblast enriched fractions. 
 
Supplementary Figure 1 Body weight changes in WT, CCL3-deficient (CCL3KO), 
CCR1-deficient (CCR1KO), or CCR5-deficient (CCR5KO) mice when treated with 3.0 % 
DSS after AOM injection. Representative results from 5 mice are shown here. Body weight 
changes were calculated on the assumption that the body weight before the DSS treatment 
was 100 %. 
 
Supplementary Figure 2 Body weight changes in CCL3-, CCR1-, or CCR5-deficient 
mice when treated with 4.5 % DSS after AOM injection. Representative results from 5 mice 
are shown here. Body weight changes were calculated on the assumption that the body 
weight before the DSS treatment was 100 %. 
 
Supplementary Figure 3 The levels of HGF, EREG, bFGF, tenascin C, MMP-2, MMP-9, 
CXCL1, and CXCL2 mRNA were quantified by real-time PCR on total RNAs extracted 
from the colon of WT (closed boxes), CCL3-deficient (open boxes), or CCR5-deficient 
mice (hatched boxes), and normalized to the level of HPRT mRNA. All values represent 
the mean + SEM (n=5 animals). *, p<0.05, WT vs. CCL3KO or CCR5KO. 
 
Supplementary Figure 4 Effects on type I collagen accumulations in HB-EGF pLIVE 
vector treated mice. HB-EGF pLIVE vector was in vivo transduced to CCL3-deficient mice 
at 42 days after the initiation of DSS intake. At 56 days after the initiation of DSS intake, 
colon tissues were obtained to determine type I collagen-positive areas. All values represent 




Supplementary Figure 5 Persistent expression of a CCR5 antagonist after in vivo transfer 
of the vector. Plasma tRANTES/CCL5 levels were determined at the indicated time 
intervals after the vector transfer. All values represent the mean ± SEM (n=3 animals). **, 
p<0.01 vs. untreated. 
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Supplementary Table S1 Sequences of primers used for qRT-PCR 
 
 








Type I collagen 
HB-EGF 
HGF 
Tenascin C 
PDGFRb 
bFGF 
MMP-2 
MMP-9 
CXCL1 
CXCL2 
Epiregulin 
tcctcctcagaccgcttt 
gcggcacgtcagatcca 
gctgacaagctcaccctctgt 
cagcaccaatgggctctga 
tccaatcttgcagtcgtgtttg 
tttgtgggtgaacggttctg 
catccgttccccctacaaga 
aggcttcagtggtttggatg 
gcaaatgcctccctggttac 
tcggataggagccacaagga 
gcaaccaaggacaatgtgtg 
caccttctccagtgtgctga 
gacccacacgtcaaactacaactc 
tgaactgcgctgtcaatgc 
tccccaaagacctgaaaacct 
tgggattcacctcaagaaca 
tcaagggcggtcaaaaagtt 
taccgccttagttcagatgg 
cctggttcatcatcgctaatc 
catggccttccgtgtttccta 
ggcagtggtggagaccttca 
gccgggaggtgtaagagaaac 
tctgggttggcacacacttg 
tggtatagccacatgcctttga 
ggaactgacccttgaaaatcca 
cttcacccttagcaccaactg 
ctacagccaccacagccaaga 
ccgaggccagctgcaat 
tgtcccatgccagatttaca 
ggagtccatagggaggaagc 
ctgtaacacacttagaagccagcag 
cttgagagtggctatgacttctgtct 
gcccgggtgtaaccatagc 
cttggggacaccttttagca 
cctttgttcagtatcttttggatgatt 
acatcgcagaccagtgtagc 
?
?
?
 
